Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the United States, European Union, Japan, South Korea, China, and other countries for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy [5, 6, 7, 8, 9, 10, 11]. This evidence concerns the gene TYK2 and psoriasis vulgaris.